Please wait while the formulary information is being retrieved.
Drug overview for IDOSE TR (travoprost):
Generic name: travoprost (TRA-voh-prost)
Drug class: Ophthalmic Antiglaucoma Agents
Therapeutic class: Ophthalmic Agents
Travoprost, a synthetic analog of naturally occurring prostaglandin F2alpha (PGF2alpha), is an ocular hypotensive agent.
No enhanced Uses information available for this drug.
Generic name: travoprost (TRA-voh-prost)
Drug class: Ophthalmic Antiglaucoma Agents
Therapeutic class: Ophthalmic Agents
Travoprost, a synthetic analog of naturally occurring prostaglandin F2alpha (PGF2alpha), is an ocular hypotensive agent.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for IDOSE TR (travoprost) have been approved by the FDA:
Indications:
Ocular hypertension
Open angle glaucoma
Professional Synonyms:
Chronic glaucoma
Compensated glaucoma
Glaucoma simplex
Increased intraocular pressure
Increased IOP
Open-angle glaucoma
Raised intraocular pressure
Simple glaucoma
Indications:
Ocular hypertension
Open angle glaucoma
Professional Synonyms:
Chronic glaucoma
Compensated glaucoma
Glaucoma simplex
Increased intraocular pressure
Increased IOP
Open-angle glaucoma
Raised intraocular pressure
Simple glaucoma
The following dosing information is available for IDOSE TR (travoprost):
The recommended adult dosage of travoprost for the treatment of open-angle glaucoma or ocular hypertension is 1 drop of a 0.004% ophthalmic solution in the affected eye(s) once daily in the evening. Travoprost 0.004%
ophthalmic solution should not be administered more frequently than once daily since more frequent dosing may paradoxically diminish the intraocular pressure (IOP)-lowering effect of the drug.
If the target IOP is not achieved, alternative or additional ocular hypotensive agents may be required. (See Uses: Ocular Hypertension and Glaucoma.)
ophthalmic solution should not be administered more frequently than once daily since more frequent dosing may paradoxically diminish the intraocular pressure (IOP)-lowering effect of the drug.
If the target IOP is not achieved, alternative or additional ocular hypotensive agents may be required. (See Uses: Ocular Hypertension and Glaucoma.)
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for IDOSE TR (travoprost):
There are 0 contraindications.
There are 0 severe interactions.
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| IOP-Lowering Prostaglandin Analogs/Bimatoprost Topical SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: When used ophthalmically to lower intraocular pressure, prostaglandin analogs may be at the top of the dose-response curve. Use of an additional prostaglandin may result in decreased effectiveness.(1) CLINICAL EFFECTS: Concurrent use of topical bimatoprost may result in decreased effectiveness of ophthalmic prostaglandin analogs and an increase in intraocular pressure.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Patients using ophthalmic prostaglandin analogs to lower intraocular pressure should be monitored for changes in their intraocular pressure.(1) Use of topical bimatoprost may need to be discontinued in patients who stop responding to their ophthalmic prostaglandin analogue. DISCUSSION: Studies have shown that the ophthalmic administration of bimatoprost twice daily is less effective at lowering intraocular pressure than ophthalmic bimatoprost administered once daily. Concurrent use of topical bimatoprost may decrease the effectiveness of ophthalmic prostaglandin analogs.(1) |
BIMATOPROST, LATISSE |
The following contraindication information is available for IDOSE TR (travoprost):
Drug contraindication overview.
The manufacturer states there are no known contraindications to the use of travoprost.
The manufacturer states there are no known contraindications to the use of travoprost.
There are 3 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Corneal dystrophy |
| Corneal transplant present |
| Ocular infection |
There are 0 severe contraindications.
There are 4 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Aphakia |
| Pseudophakia |
| Risk of angle-closure glaucoma due to narrow angle of anterior chamber of eye |
| Uveitis |
The following adverse reaction information is available for IDOSE TR (travoprost):
Adverse reaction overview.
Ocular hyperemia occurred in approximately 30-50% of patients who received travoprost ophthalmic solution in clinical trials. Up to 3% of patients discontinued therapy because of conjunctival hyperemia. Decreased visual acuity, ocular discomfort, foreign body sensation, pain, and pruritus have been reported in approximately 5-10% of patients who received travoprost ophthalmic solution in clinical trials.
Adverse ocular effects reported in approximately 1-4% of patients include abnormal vision, blepharitis, blurred vision, cataract, conjunctivitis, corneal staining, dry eye, iris discoloration, keratitis, lid margin crusting, ocular inflammation, photophobia, subconjunctival hemorrhage, and tearing. Adverse nonocular events reported in approximately 1-5% of patients include allergy, angina pectoris, anxiety, arthritis, back pain, bradycardia, bronchitis, chest pain, cold/flu syndrome, depression, dyspepsia, GI disorder, headache, hypercholesterolemia, hypertension, hypotension, infection, pain, prostate disorder, sinusitis, urinary incontinence, and urinary tract infection.
Ocular hyperemia occurred in approximately 30-50% of patients who received travoprost ophthalmic solution in clinical trials. Up to 3% of patients discontinued therapy because of conjunctival hyperemia. Decreased visual acuity, ocular discomfort, foreign body sensation, pain, and pruritus have been reported in approximately 5-10% of patients who received travoprost ophthalmic solution in clinical trials.
Adverse ocular effects reported in approximately 1-4% of patients include abnormal vision, blepharitis, blurred vision, cataract, conjunctivitis, corneal staining, dry eye, iris discoloration, keratitis, lid margin crusting, ocular inflammation, photophobia, subconjunctival hemorrhage, and tearing. Adverse nonocular events reported in approximately 1-5% of patients include allergy, angina pectoris, anxiety, arthritis, back pain, bradycardia, bronchitis, chest pain, cold/flu syndrome, depression, dyspepsia, GI disorder, headache, hypercholesterolemia, hypertension, hypotension, infection, pain, prostate disorder, sinusitis, urinary incontinence, and urinary tract infection.
There are 1 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Ocular hypertension |
None. |
| Rare/Very Rare |
|---|
| None. |
There are 13 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Dry eye Iritis Visual field defect |
Conjunctival hyperemia Ocular pain Reduced visual acuity |
| Rare/Very Rare |
|---|
|
Blepharitis Conjunctival hemorrhage Corneal abrasion Ocular irritation Photophobia Punctate keratitis Vitreous detachment |
The following precautions are available for IDOSE TR (travoprost):
Use of travoprost ophthalmic solution in pediatric patients younger than 16 years of age is not recommended because of potential safety concerns related to increased pigmentation following long-term use. (See Pigmentation under Cautions: Warnings/Precautions.)
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Category C. (See Users Guide.) Teratogenic effects, including skeletal, external, and visceral malformations, were observed in rats receiving IV travoprost at dosages up to 250 times the maximum recommended human ocular dosage but not following IV administration in rats or following subcutaneous administration in mice at dosages up to 75 or 25 times, respectively, the maximum recommended human ocular dosage. Increased postimplantation losses and decreased fetal viability were observed in rats and mice at dosages exceeding 75 and 7.5
times, respectively, the maximum recommended human ocular dosage. Increased postnatal mortality, decreased neonatal body weight gain, and adverse effects on neonatal development also have been observed in animal studies. There are no adequate and well-controlled studies using travoprost ophthalmic solution in pregnant women. Travoprost ophthalmic solution should be used during pregnancy only if the potential benefits justify the potential risk to the fetus.
times, respectively, the maximum recommended human ocular dosage. Increased postnatal mortality, decreased neonatal body weight gain, and adverse effects on neonatal development also have been observed in animal studies. There are no adequate and well-controlled studies using travoprost ophthalmic solution in pregnant women. Travoprost ophthalmic solution should be used during pregnancy only if the potential benefits justify the potential risk to the fetus.
Travoprost and/or its metabolites are distributed into milk in rats; it is not known whether travoprost and/or its metabolites are distributed into human milk. Caution is advised when travoprost ophthalmic solution is used in nursing women.
No overall differences in safety and efficacy of travoprost ophthalmic solution have been observed between geriatric patients and younger adults.
The following prioritized warning is available for IDOSE TR (travoprost):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for IDOSE TR (travoprost)'s list of indications:
| Ocular hypertension | |
| H40.05 | Ocular hypertension |
| H40.051 | Ocular hypertension, right eye |
| H40.052 | Ocular hypertension, left eye |
| H40.053 | Ocular hypertension, bilateral |
| H40.059 | Ocular hypertension, unspecified eye |
| Open angle glaucoma | |
| H40.1 | Open-angle glaucoma |
| H40.10 | Unspecified open-angle glaucoma |
| H40.10x0 | Unspecified open-angle glaucoma, stage unspecified |
| H40.10x1 | Unspecified open-angle glaucoma, mild stage |
| H40.10x2 | Unspecified open-angle glaucoma, moderate stage |
| H40.10x3 | Unspecified open-angle glaucoma, severe stage |
| H40.10x4 | Unspecified open-angle glaucoma, indeterminate stage |
| H40.11 | Primary open-angle glaucoma |
| H40.111 | Primary open-angle glaucoma, right eye |
| H40.1110 | Primary open-angle glaucoma, right eye, stage unspecified |
| H40.1111 | Primary open-angle glaucoma, right eye, mild stage |
| H40.1112 | Primary open-angle glaucoma, right eye, moderate stage |
| H40.1113 | Primary open-angle glaucoma, right eye, severe stage |
| H40.1114 | Primary open-angle glaucoma, right eye, indeterminate stage |
| H40.112 | Primary open-angle glaucoma, left eye |
| H40.1120 | Primary open-angle glaucoma, left eye, stage unspecified |
| H40.1121 | Primary open-angle glaucoma, left eye, mild stage |
| H40.1122 | Primary open-angle glaucoma, left eye, moderate stage |
| H40.1123 | Primary open-angle glaucoma, left eye, severe stage |
| H40.1124 | Primary open-angle glaucoma, left eye, indeterminate stage |
| H40.113 | Primary open-angle glaucoma, bilateral |
| H40.1130 | Primary open-angle glaucoma, bilateral, stage unspecified |
| H40.1131 | Primary open-angle glaucoma, bilateral, mild stage |
| H40.1132 | Primary open-angle glaucoma, bilateral, moderate stage |
| H40.1133 | Primary open-angle glaucoma, bilateral, severe stage |
| H40.1134 | Primary open-angle glaucoma, bilateral, indeterminate stage |
| H40.119 | Primary open-angle glaucoma, unspecified eye |
| H40.1190 | Primary open-angle glaucoma, unspecified eye, stage unspecified |
| H40.1191 | Primary open-angle glaucoma, unspecified eye, mild stage |
| H40.1192 | Primary open-angle glaucoma, unspecified eye, moderate stage |
| H40.1193 | Primary open-angle glaucoma, unspecified eye, severe stage |
| H40.1194 | Primary open-angle glaucoma, unspecified eye, indeterminate stage |
| H40.12 | Low-tension glaucoma |
| H40.121 | Low-tension glaucoma, right eye |
| H40.1210 | Low-tension glaucoma, right eye, stage unspecified |
| H40.1211 | Low-tension glaucoma, right eye, mild stage |
| H40.1212 | Low-tension glaucoma, right eye, moderate stage |
| H40.1213 | Low-tension glaucoma, right eye, severe stage |
| H40.1214 | Low-tension glaucoma, right eye, indeterminate stage |
| H40.122 | Low-tension glaucoma, left eye |
| H40.1220 | Low-tension glaucoma, left eye, stage unspecified |
| H40.1221 | Low-tension glaucoma, left eye, mild stage |
| H40.1222 | Low-tension glaucoma, left eye, moderate stage |
| H40.1223 | Low-tension glaucoma, left eye, severe stage |
| H40.1224 | Low-tension glaucoma, left eye, indeterminate stage |
| H40.123 | Low-tension glaucoma, bilateral |
| H40.1230 | Low-tension glaucoma, bilateral, stage unspecified |
| H40.1231 | Low-tension glaucoma, bilateral, mild stage |
| H40.1232 | Low-tension glaucoma, bilateral, moderate stage |
| H40.1233 | Low-tension glaucoma, bilateral, severe stage |
| H40.1234 | Low-tension glaucoma, bilateral, indeterminate stage |
| H40.129 | Low-tension glaucoma, unspecified eye |
| H40.1290 | Low-tension glaucoma, unspecified eye, stage unspecified |
| H40.1291 | Low-tension glaucoma, unspecified eye, mild stage |
| H40.1292 | Low-tension glaucoma, unspecified eye, moderate stage |
| H40.1293 | Low-tension glaucoma, unspecified eye, severe stage |
| H40.1294 | Low-tension glaucoma, unspecified eye, indeterminate stage |
| H40.13 | Pigmentary glaucoma |
| H40.131 | Pigmentary glaucoma, right eye |
| H40.1310 | Pigmentary glaucoma, right eye, stage unspecified |
| H40.1311 | Pigmentary glaucoma, right eye, mild stage |
| H40.1312 | Pigmentary glaucoma, right eye, moderate stage |
| H40.1313 | Pigmentary glaucoma, right eye, severe stage |
| H40.1314 | Pigmentary glaucoma, right eye, indeterminate stage |
| H40.132 | Pigmentary glaucoma, left eye |
| H40.1320 | Pigmentary glaucoma, left eye, stage unspecified |
| H40.1321 | Pigmentary glaucoma, left eye, mild stage |
| H40.1322 | Pigmentary glaucoma, left eye, moderate stage |
| H40.1323 | Pigmentary glaucoma, left eye, severe stage |
| H40.1324 | Pigmentary glaucoma, left eye, indeterminate stage |
| H40.133 | Pigmentary glaucoma, bilateral |
| H40.1330 | Pigmentary glaucoma, bilateral, stage unspecified |
| H40.1331 | Pigmentary glaucoma, bilateral, mild stage |
| H40.1332 | Pigmentary glaucoma, bilateral, moderate stage |
| H40.1333 | Pigmentary glaucoma, bilateral, severe stage |
| H40.1334 | Pigmentary glaucoma, bilateral, indeterminate stage |
| H40.139 | Pigmentary glaucoma, unspecified eye |
| H40.1390 | Pigmentary glaucoma, unspecified eye, stage unspecified |
| H40.1391 | Pigmentary glaucoma, unspecified eye, mild stage |
| H40.1392 | Pigmentary glaucoma, unspecified eye, moderate stage |
| H40.1393 | Pigmentary glaucoma, unspecified eye, severe stage |
| H40.1394 | Pigmentary glaucoma, unspecified eye, indeterminate stage |
| H40.14 | Capsular glaucoma with pseudoexfoliation of lens |
| H40.141 | Capsular glaucoma with pseudoexfoliation of lens, right eye |
| H40.1410 | Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified |
| H40.1411 | Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage |
| H40.1412 | Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage |
| H40.1413 | Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage |
| H40.1414 | Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage |
| H40.142 | Capsular glaucoma with pseudoexfoliation of lens, left eye |
| H40.1420 | Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified |
| H40.1421 | Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage |
| H40.1422 | Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage |
| H40.1423 | Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage |
| H40.1424 | Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage |
| H40.143 | Capsular glaucoma with pseudoexfoliation of lens, bilateral |
| H40.1430 | Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified |
| H40.1431 | Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage |
| H40.1432 | Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage |
| H40.1433 | Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage |
| H40.1434 | Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage |
| H40.149 | Capsular glaucoma with pseudoexfoliation of lens, unspecified eye |
| H40.1490 | Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified |
| H40.1491 | Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage |
| H40.1492 | Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage |
| H40.1493 | Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage |
| H40.1494 | Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage |
| H40.15 | Residual stage of open-angle glaucoma |
| H40.151 | Residual stage of open-angle glaucoma, right eye |
| H40.152 | Residual stage of open-angle glaucoma, left eye |
| H40.153 | Residual stage of open-angle glaucoma, bilateral |
| H40.159 | Residual stage of open-angle glaucoma, unspecified eye |
Formulary Reference Tool